Lexaria Bioscience Corp. current report, 10 January 2017 (NASDAQ:LEXX)

This Form 8-K was filed on January 10, 2017, by Lexaria Bioscience Corp., a Nevada corporation headquartered in Kelowna, BC, Canada. The report discloses unregistered sales of equity securities and Regulation FD disclosures related to capital raised on the same date.

Key Financial Metrics

The filing details a specific capital raise event rather than periodic financial performance metrics such as revenue, profit, or operating cash flow.

Total Proceeds Received: US$33,029.25
Source of Funds: Exercise of previously granted stock options and warrants by third parties (non-officers/directors).
Shares Issued from Options: 151,500 common shares (exercise prices ranged from US$0.10 to US$0.2273).
Shares Issued from Warrants: 12,375 common shares (exercise prices of US$0.15 and US$0.14).
New Warrants Issued: 500,000 warrants issued to Correlation Capital Inc. (exercise price US$0.44, one-year term).
Transaction Costs: No commissions or placement fees were paid.
Use of Proceeds: General corporate purposes.

Note: The filing text does not provide clear values for revenue, net income, operating margins, total debt, or liquidity ratios.

Material Changes

The primary material change is the increase in outstanding common shares and the issuance of new warrants. The company received immediate cash inflow of approximately US$33,000. There is no comparative period data provided in this specific filing to quantify changes in financial position versus prior periods.

Outlook, Risks, and Contingencies

Management Commentary: The proceeds are designated for general corporate purposes. The transaction involved third-party investors, indicating no insider participation in this specific exercise.

Risks and Contingencies: The securities issued in this transaction were not registered under the United States Securities Act of 1933. Consequently, they may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Investor Verification Checklist

Verify the total number of outstanding shares post-issuance (163,875 new shares issued in this transaction).
Confirm the dilution impact of the 500,000 new warrants issued to Correlation Capital Inc.
Review the company's latest 10-K or 10-Q for baseline liquidity and debt levels, as this 8-K does not contain balance sheet data.
Check for any subsequent filings regarding the use of the US$33,029.25 proceeds.